Hims & Hers Health rose in after-hours trading after revealing talks with Novo Nordisk about offering Wegovy’s new obesity pill. The telehealth firm also beat Q3 revenue estimates, reporting nearly $600 million in sales and strong subscriber growth.
President Trump signaled major price reductions for Novo Nordisk's Ozempic, potentially lowering costs to $150. This announcement, made amid ongoing drug price negotiations, caused significant drops in pharma stock prices.
Hers launched specialty care for menopause/perimenopause, offering women personalized plans including prescription pills, patches, or creams.
Bank of America maintains Underperform rating on Hims & Hers, slashing Q4 revenue forecast 6.5% below Street estimates to $590M, citing weak momentum and deferred revenue concerns.
Novo Nordisk is planning a strategic digital launch for its forthcoming obesity pill, targeting telehealth sites like Ro and WeightWatchers in early 2026 to recapture market share lost to rival Eli Lilly and combat the rise of copycat drugs.
The FDA warned Hims & Hers for misleading ads on compounded weight-loss drugs. Hims claimed "same active ingredient" as FDA-approved drugs like Ozempic, but compounded versions aren't FDA-approved. The FDA says these claims are false and misleading.
